Transcription factor SP1 drives the malignant progression of oral squamous cell carcinoma and M2 macrophage polarization through transcription activation-mediated upregulation CLEC7A.

转录因子 SP1 通过转录激活介导的 CLEC7A 上调,驱动口腔鳞状细胞癌的恶性进展和 M2 巨噬细胞极化

阅读:11
作者:Xiao Zhen, Li Jiayi, Fan Shuxia, Wang Yu, Jin Qingsong
Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral cavity. Previous studies have suggested that C-Type Lectin Domain Containing 7A (CLEC7A) could affect human cancer progression by regulating M2 macrophage polarization. However, the role of the molecular mechanism of CLEC7A involved in OSCC progression is poorly defined. GEPIA database was used to analyze CLEC7A and specificity protein 1 (SP1) expression, and the relationship between CLEC7A and M2-type macrophage markers (CD163 and MRC1). CLEC7A and SP1 levels were determined using real-time quantitative polymerase chain reaction (RT-qPCR). CLEC7A, SP1, RHOA, RAC1, E-cadherin, and Vimentin protein levels were detected using western blot. Cell proliferation, apoptosis, migration, and invasion were detected by Colony formation, flow cytometry, and Transwell assays. The proportion of CD11b(+)CD86(+) positive cells was detected using flow cytometry. Binding between SP1 and CLEC7A promoter was predicted by JASPAR, and validated using Chromatin immunoprecipitation (ChIP) and dual-luciferase reporter assays. The biological role of SP1 on OSCC tumor growth was examined by the xenograft tumor model in vivo. CLEC7A and SP1 expression levels were increased in OSCC tissues and cell lines. Furthermore, CLEC7A deficiency could repress OSCC cell proliferation, migration, invasion, M2-type macrophage polarization, and induce cell apoptosis in vitro, as well as hinder tumor growth in vivo. At the molecular level, SP1 was a transcription factor of CLEC7A and promoted CLEC7A transcription via binding to its promoter regions. SP1-activated CLEC7A could facilitate OSCC cell malignant behaviors and M2 macrophage polarization, providing a possible therapeutic target for OSCC treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10616-025-00787-7.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。